Category: us corporate news

us corporate news

Palvella Therapeutics Announces Positive Phase 3 Results for QTORIN Rapamycin, Prepares NDA Submission and U.S. Launch for Rare Skin Disease Therapies

Minichart

March 31, 2026

Palvella Therapeutics Announces Landmark FY2025 Results and ...

Continue Reading 0

us corporate news

BTCS Inc. Announces Change of Independent Registered Public Accounting Firm in 2026

Minichart

March 31, 2026

BTCS Inc. Announces Change in Independent Auditor BTCS...

Continue Reading 0

us corporate news

1606 Corp. Advances Data Center Strategy with Key Acquisition and Power Infrastructure Focus in 2026

Minichart

March 31, 2026

1606 Corp. Annual Report: Strategic Shift to Data Center Inf...

Continue Reading 0

us corporate news

SiteOne Landscape Supply Announces Executive Transition: Scott Salmon to Retire, Daniel Laughlin Appointed EVP of Strategy and Development

Minichart

March 31, 2026

SiteOne Landscape Supply Announces Leadership Transition ...

Continue Reading 0

us corporate news

Emmaus Life Sciences Reports 2025 Financial Results: Net Revenue Down 25%, New U.S. Strategy Announced

Minichart

March 31, 2026

Emmaus Life Sciences Reports 2025 Annual Results: Navigates ...

Continue Reading 0

us corporate news

Caribou Biosciences Granted FDA RMAT Designation for CB-011 Allogeneic Anti-BCMA CAR-T Cell Therapy

Minichart

March 31, 2026

Caribou Biosciences Receives FDA RMAT Designation for CB-011...

Continue Reading 0

us corporate news

Purple Innovation Reports Q4 and Full Year 2025 Results: Returns to Adjusted EBITDA Profitability, Gross Margin Tops 40% Target

Minichart

March 31, 2026

Purple Innovation Reports Q4 & Full Year 2025 Results: Key F...

Continue Reading 0

us corporate news

IMUNON Reports 2025 Financial Results and Highlights Breakthrough Phase 3 Progress for IMNN-001 in Advanced Ovarian Cancer

Minichart

March 31, 2026

IMUNON, Inc. Reports 2025 Financial Results and Major Clinic...

Continue Reading 0

us corporate news

MiNK Therapeutics Reports 2025 Results and Advances Phase 2 iNKT Cell Therapy Programs for ARDS, GVHD, and Oncology

Minichart

March 31, 2026

MiNK Therapeutics 2025 Financial Results and Strategic Updat...

Continue Reading 0

us corporate news

Solésence, Inc. Reports Record $62.1 Million Revenue for 2025 and Announces Strategic Growth Initiative

Minichart

March 31, 2026

Solesence, Inc. – Form 8-K and Results of Operations Sol...

Continue Reading 0